Secondary central nervous system lymphoma, which is also referred to as metastatic lymphoma, is an aggressive disease. It is rare, and nearly always fatal occurring in <1% of indolent systemic lymphomas, and in <5% of aggressive systemic lymphomas1.
It tends to occurs between 5-12 months after the primary lymphoma diagnosis, and most lesions occur in periventricular or central hemispheric white matter2. It has been shown that CNS lymphoma relapses occur earlier in patients receiving R-CHOP as compared to those receiving CHOP chemotherapy regimes3.